Clinical Trial Update: A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations [Phase 3]

View source ↗

Summary

A Phase III trial evaluating neoadjuvant Sintilimab plus chemotherapy for non-small cell lung cancer without driver mutations is in progress, with status curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Chemotherapy (neoadjuvant)
• Sintilimab (sintilimab)

Snippet

Sponsor: Tongji University | Conditions: NSCLC, Stage IIIA, EGF-R Negative Non-Small Cell Lung Cancer | Phase 3 | Status: UNKNOWN